-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $53

Benzinga·03/11/2026 18:22:17
Listen to the news
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $47 to $53.